Market share analysis and key trend analysis are the two other major success factors in this Asia-Pacific CAR-T Cell Therapy Treatment Market report. The key research methodology used here by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. It is a proficient and a comprehensive report that focuses on primary and secondary market drivers, market share, leading segments and geographical analysis. Integrated approaches and latest technology have been used in the    Asia-Pacific CAR-T Cell Therapy Treatment report for the best results while generating such market research report.

 

Asia-Pacific CAR-T cell therapy treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 30.8% in the forecast period of 2021 to 2028 and is expected to reach USD 267.08 million by 2028. Increase in usage of CAR-T cell therapy for the treatment of cancer and infectious diseases and increasing prevalence of cancer are the major drivers which propelled the demand of the market in the forecast period.

 

 

 

The demand for the CAR-T cell therapy treatment has been increased in both developed as well as in developing countries and the reason behind this is a rise in awareness about immunotherapies for the CAR-T cell therapy treatment and increase in investment for research and development. The CAR-T cell therapy treatment market will grow in the forecasted period with the increasing prevalence of cancers.

 

The major companies which are dealing in the CAR-T cell therapy treatment are Autolus, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AbbVie Inc., Novartis AG, Cartherics Pty ltd, CARINA BIOTECH, and TC BIOPHAR Mamong others global and domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

 

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the CAR-T cell therapy treatment market.

 

 

In February 2021, AbbVie Inc. had announced the collaboration with the Caribou Biosciences which is the biotechnology leading company in the clinical-stage CRISPR genome editing. The companies have entered into the collaboration and license agreement for the research and development of the chimeric antigen receptor (CAR)-T cell therapeutics. The allogeneic CAR-T cell therapies showed positive impact on the cancer patients but the rejection of CAR-T cells by the host immune system has been considered as one of the challenge for the researchers therefore, Caribou Biosciences technology that is CRISPR genome editing will be engineered to the CAR-T cells so that it can endure the host immune attack which can benefit the large patient population. This collaboration helped the company to be considered in the market who is involved in the development of the innovative CAR-T therapies and overcome the issues related with this therapy which will increase the status in the market and directly increases their company growth.

 

In July 2020, Kite Pharma (a subsidiary of Gilead Sciences, Inc.) had announced that the company has received the USFDA approval for Tecartus (brexucabtagene autoleucel) which was previously known as KTE-X19 which was considered as only CAR-T cell therapy for the treatment of refractory mantle cell lymphoma (MCL). The product has been granted with Breakthrough Therapy Designation (BTD) from FDA. The single infusion of this product found 62% had showed complete response and 87% patients’ responded positive. This product is considered as the first cell therapy for the patients suffering from relapsed/refractory MCL. This helped the company to get recognized as one of the company to develop a CAR-T cell therapy for the treatment of the refractory large B-cell lymphoma after the two or three therapies which will increase the demand in the market.

 

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the CAR-T cell therapy treatment market which also provides the benefit for organization to improve their offering for CAR-T cell therapy.

 

 

CAR-T cell therapy treatment market also provides you with detailed market analysis for every country growth in CAR-T cell therapy treatment industry with CAR-T cell therapy treatment drugs sales, impact of advancement in the CAR-T cell therapy treatment technology and changes in regulatory scenarios with their support for the CAR-T cell therapy treatment market. The data is available for historic period 2010 to 2019.

 

 

 

Chapter 1: Market overview

 

Chapter 2:  Asia-Pacific CAR-T Cell Therapy Treatment Marktet

 

Chapter 3: Regional analysis of the  Asia-Pacific CAR-T Cell Therapy Treatment industry

 

Chapter 4:  Asia-Pacific CAR-T Cell Therapy Treatment segmentation based on types and applications

 

Chapter 5: Revenue analysis based on types and applications

 

Chapter 6: Market share

 

Chapter 7: Competitive Landscape

 

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

 

Chapter 9: Gross Margin and Price Analysis

 

 

 

 

 

 

 

 

An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune.

 

Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.

 

 

Data Bridge Market Research

 

US: +1 888 387 2818

 

United Kingdom: +44 208 089 1725

 

Hong Kong: +852 8192 7475

 

Email: – sopan.gedam@databridgemarketresearch.com